St. Jude Care & Treatment

Menu

Close

Recruiting

SJALL23T: Treatment of Newly Diagnosed Leukemia/Lymphoma

About this study

T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LLy, a type of non-Hodgkin lymphoma), and mixed phenotype acute leukemia (MPAL) are usually treated with a mix of cancer-fighting drugs called chemotherapy. Chemotherapy kills the leukemia and lymphoma cells that are in the blood and the bone marrow. Four to 7 chemotherapy drugs are usually used during the first part of treatment.

This study will see if a new mix, including 3 new chemotherapy drugs, is better at getting rid of leukemia and lymphoma than the usual 4 to 7 drugs. The 3 new medicines are called venetoclax, dasatinib, and bortezomib. Venetoclax and dasatinib are approved by the U.S Food and Drug Administration (FDA) to treat adult patients with certain types of leukemia. These drugs are not approved by the FDA to treat childhood T-ALL or MPAL. Bortezomib is not FDA approved for children. It is recommended as standard of care for patients with T-LLy.

The goal of this treatment is to compare the effects (good and/or bad) of adding venetoclax, dasatinib, or bortezomib to standard chemotherapy for newly diagnosed T-ALL, T-LLy and MPAL.

Eligibility overview

  • Ages 1 – 18 years
  • Enrolled in INITIALL clinical trial
  • No chemotherapy unless given during or allowed by INITIALL
  • No known HIV infection, no active hepatitis B, and no active hepatitis C

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

SJALL23T: Adding Dasatinib or Venetoclax to Improve Responses in Children with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T-LLY) or Mixed Phenotype Acute Leukemia (MPAL)

Study goal:

To compare the effects of adding venetoclax, dasatinib, or bortezomib to standard chemotherapy for T-ALL, T-LLy,and MPAL, and to learn more about the biological and genetic or genomic traits that predict treatment success and toxicity

Diagnosis:

T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma, mixed phenotype acute leukemia

Age:

1-18 years

Clinical trials categories:

Childhood Cancer Leukemia Non-Hodgkin Lymphoma Acute Lymphoblastic Leukemia (ALL)

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more